FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Source: Benzinga ·

FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use. This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at ho

Read the full story at Benzinga

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk